Information Library
Phase I/IIa
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Early Phase Optimization Strategies
November 18, 2009
As payers balk at rising drug prices and patent expirations threaten the industry’s revenue streams, pharmaceutical companies worldwide are looking for ways to cut costs associated with drug development and, simultaneously, speed the process up. -
Drug Information Association (DIA) US 2010
June 13 - June 16, 2010
Exhibit Dates: June 13 - 16, 2010 Exhibitor Booth Number: 1035 Quintiles Speakers: TBD -
ASCO 2010 Annual Meeting
June 4 - June 8, 2010
Exhibit Dates: June 5 - 7, 2010 Exhibitor Booth Number: 2053 -
Drug Information Association (DIA) Europe 2010
March 8 - March 10, 2010
22nd Annual EuroMeeting for the Drug Information Association -
QUINTILES PARTNERS WITH FOUNDATION TRUST & UNIVERSITY TO IMPROVE PATIENT CARE AND DRIVE EFFICIENCY IN CLINICAL RESEARCH
October 26, 2009 - A significant step in driving innovation, improving patient care and increasing efficiency in early stage clinical research was taken today with the announcement that two of the UK’s leading institutions - Guy’s and St Thomas’ NHS Foundation Trust and King’s College London - have signed a collaborative agreement with Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. -
QUINTILES INCREASES CAPACITY TO SUPPORT EUROPEAN CLINICAL TRIALS
September 24, 2009 - Quintiles Transnational Corp. today announced the opening of an expanded regional facility near Edinburgh, Scotland. Located within the Alba Campus, a research and development center near Edinburgh, the 115,000-square-foot building hosts more than 500 employees and has space for Quintiles Clinical Development Services, including Project Management, Regulatory Affairs and Data Management. -
Changing the Face of Cancer Research
August 31, 2009
Christopher Ung, Vice President, Strategic Business & Operations, Oncology, at TMD, a Quintiles Central Laboratory, explains how advances in biomarker technology are ushering in a new era of cancer therapy development. -
Phase One Services: Professor Anders E. Grahnen
July 24, 2009
With the current high costs of drug development, it's crucial that you can establish the potential success of your agent before the end of Phase II. Our market-leading expertise in biomarkers and specialist techniques can help you do just that. -
Phase One Services: Dr. Brock G. Guernsey
July 24, 2009
Why wait two months to see your data and delay critical decisions when we can deliver your data within a week using electronic bedside data entry? Consider what a 2-month delay means to your drug's development plan? Whether you've done preclinical work and need a rapid Proof of Concept study or are looking for a benchmark of how your drug performs in a specific disease state, we can help. -
Phase One Services: Dr. Elizabeth Allen
July 24, 2009
In 2008 TUFTS reported that it costs over $1 billion to develop a new biopharmaceutical product. Half of this investment occurs in the later stages of testing. Thankfully at Quintiles, we provide accurate and correct Phase I and IIa data quickly. We can help you make smart, safe decisions earlier to avoid repeating costly studies later.